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Summary
Objective: Conventional treatment of osteoarthritis (OA) with non-steroidal anti-inﬂammatory drugs is associated with serious gastrointestinal
side effects and in view of the recent withdrawal of some cyclo-oxygenase-2 inhibitors, identifying safer alternative treatment options is
needed. The objective of this systematic review is to evaluate the existing evidence from randomised controlled trials of two chemically related
nutritional supplements, dimethyl sulfoxide (DMSO) and methylsulfonylmethane (MSM) in the treatment of OA to determine their efﬁcacy and
safety proﬁle.
Methods: The electronic databases [Cochrane Library, Medline, Embase, Amed, Cinahl and NeLH (1950 to November 2007)] were searched.
The search strategy combined terms: osteoarthritis, degenerative joint disorder, dimethyl sulfoxide, DMSO, methylsulfonylmethane, MSM,
clinical trial; double-blind, single blind, RCT, placebo, randomized, comparative study, evaluation study, control. Inclusion and exclusion
criteria were applied. Data were extracted and quality was assessed using the JADAD scale.
Results: Six studies were included [evaluating a total of 681 patients with OA of the knee for DMSO (N¼ 297 on active treatment); 168
patients for MSM (N¼ 52 on active treatment)]. Two of the four DMSO trials, and both MSM trials reported signiﬁcant improvement in pain
outcomes in the treatment group compared to comparator treatments, however, methodological issues and concerns over optimal dosage
and treatment period, were highlighted.
Conclusion: No deﬁnitive conclusion can currently be drawn for either supplement. The ﬁndings from all the DMSO studies need to be viewed
with caution because of poor methodology including; possible unblinding, and questionable treatment duration and dose. The data from the
more rigorous MSM trials provide positive but not deﬁnitive evidence that MSM is superior to placebo in the treatment of mild to moderate OA
of the knee. Further studies are now required to identify both the optimum dosage and longer-term safety of MSM and DMSO, and deﬁnitive
efﬁcacy trials.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is the most common of all joint disorders
and affects over 30 million people in the US and one in10
people aged 35e75 in the UK1. Non-steroidal anti-inﬂam-
matory drugs (NSAIDs) are commonly prescribed and
although effective are associated with serious gastrointesti-
nal (GI) side effects2,3. NSAIDs’ users are up to 5.5 times
more likely to experience side effects which require hospi-
talisation than non-users; 12,000 admissions and approxi-
mately 2000 deaths are attributed to NSAIDs in the UK
every year4. Patients with OA look to complementary and
alternative medicine (CAM) to gain symptomatic relief and
avoid iatrogenic illness with OA being the sixth most*Address correspondence and reprint requests to: Dr Sarah
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1277common condition treated with CAM5. CAM use in patients
with OA is substantially greater than that in the general pop-
ulation with a reported prevalence of up to 90%6,7.
Both dimethyl sulfoxide (DMSO, an organic form of sul-
phur commercially prepared from lignin) and its oxidised
form, methylsulfonylmethane (MSM, occurring in green
plants fruits and vegetables) have been used to treat ar-
thritic conditions8. Both have similar pharmacological prop-
erties and their putative effects and mechanisms have been
reviewed previously (MSM9e11; DMSO12e15; both16).
Ameye and Chee conducted a systematic review of neutri-
ceuticals in OA and concluded that MSM showed ‘‘moder-
ate’’ evidence of efﬁcacy; they did not evaluate DMSO.
MSM and DMSO reduce peripheral pain17e19, inﬂamma-
tion20 and arthritis21, and might inhibit the degenerative
changes occurring in OA22. These compounds may act
through their ability to stabilise cell membranes, slow or
stop leakage from injured cells and scavenge hydroxyl
free radicals which trigger inﬂammation18,20,23e28. Their
sulphur content can rectify dietary deﬁciencies of sulphur
improving cartilage formation29,30.
1278 S. Brien et al.: DMSO and MSM in osteoarthritisDMSO is a topical agent, diluted for therapeutic use [con-
centrations are expressed %(v/v)] and penetrates the skin;
it is also used as a carrier to aid penetration of other med-
ications19,23,31. Clinicians are advised to prescribe DMSO
for OA for at least 3 months to ensure a clinical effect. How-
ever, the optimum dosage for this supplement in OA has not
been clearly evaluated as no dose ranging studies have
been conducted. Previous empirical reports suggest that
the therapeutic concentrations of DMSO are 60e90%14,32
and that doses of under 10% are clinically inactive32e34.
There is limited formal safety data and no long-term assess-
ment of DMSO although the toxicity of oral DMSO appears
very low (LD50¼ 14.5 g/kg body weight). Adverse effects
associated with topical DMSO administration have been re-
ported (GI upset, skin irritation, and garlic like taste, breath
and body odour)35,36. Its garlic odour can compromise
blinding in double-blinded trials.
MSM is used orally and topically. Like DMSO, the treat-
ment duration for OA is at least 3 months. The optimum
dosage has not been clearly deﬁned as no dose ranging
studies have been carried out. The suggested oral thera-
peutic doses are 4e6 g/d37,38, although doses of up to
20 g/d have also been used39; over the counter prepara-
tions are typically 1e5 g daily40. There is limited formal
safety data and no long-term assessment. However, MSM
is rapidly excreted from the body41,42 and animal toxicity
studies of MSM showed only minor adverse events using
doses of 1.5 g/kg and 2.0 g/kg of MSM for 90 days. This
dose represents a human dose of 30e42 g/d, which is
equivalent to 5e7 times the proposed maximum recommen-
ded human dose of 6 g/d43. A further study conﬁrmed MSM
had no toxic effects on either pregnant rats or their foetus44.
Only minor adverse effects are associated with MSM ad-
ministration in humans and include allergy, GI upsets and
skin rashes45.
A review assessing the effectiveness and safety of both
DMSO and MSM in OA is timely and pertinent because of
the withdrawal of some cyclooxygenase (COX)-2 inhibitors3
as well as the frequent use of nutritional supplements by this
patient group6,7. The speciﬁc objective of this systematic re-
view is to evaluate the existing evidence from randomised
controlled trials (RCTs) of DMSO or MSM in the treatment
of OA to determine their efﬁcacy and safety proﬁle.MethodsLITERATURE SEARCH STRATEGY AND STUDY SELECTIONOnly randomised or quasi-RCTs comparing DMSO or MSM to other ther-
apies or to no therapy in the treatment of OA were included. Electronic data-
bases [Cochrane Library, Medline, Embase, Amed, Cinahl, and NeLH
(Complementary and Alternative Medicine Specialist Library)] were used to
identify studies between 1950 and November 2007. Citation tracking was un-
dertaken to identify unpublished trials. As numerous pharmaceutical compa-
nies market DMSO, it was impractical to contact each of them for
unpublished data. Free text searches were performed on each database
with the following keywords: osteoarthritis, degenerative joint disorder, di-
methyl sulfoxide, DMSO, methylsulfonylmethane, MSM, clinical trial; double-
blind, single blind, RCT, placebo, randomized, comparative study, evaluation
study, control.DATA EXTRACTIONRCTs were included if they were in humans; reported comparison of
DMSO or MSM to either placebo, or standard treatment in OA; used vali-
dated outcome measures for OA; and did not include patients with other joint
pathology. JADAD was used to assess the reporting quality and methodolog-
ical rigour46. The trials were assessed by four of the authors independently;
any disagreements were discussed and resolved. The authors reported
on other measures of internal validity (dosage, treatment period, andappropriateness of statistical analysis) and external validity (inclusion and
exclusion criteria, baseline characteristics, trial setting, and outcome mea-
sures). Additional data such as joint location, age of sample population, com-
pliance, statistical evaluation, results and adverse effects were extracted and
tabulated.
ResultsRESULTS OF SEARCH STRATEGYSeven RCTs were identiﬁed (1971e2006). The NeLH
search strategy identiﬁed four31,37,38,47; Embase identiﬁed
(1980e2007) ﬁve, two of which were additional to those
identiﬁed by NeLH48,49. The searches on the other data-
bases did not identify any additional RCTs [Cochrane (three
citations); Medline (1950e2007, three citations); Amed
(1985e2007, one citation); and Cinahl (1982e2007, zero
citation). Citation tracking identiﬁed one further RCT50.
Five of the RCTs were in English31,37,38,47,50 and two in
German48,49. Five were placebo-controlled; the remaining
two were comparator trials, one an equivalence trial48. How-
ever, the trial by Roth47 was excluded as its aim was not to
evaluate the efﬁcacy or effectiveness of DMSO; it assessed
the efﬁcacy of Diclofenac (DF) using DMSO as a carrier
vehicle to enhance drug uptake. Six RCTs were available
for analysis, four assessing DMSO31,48e50 (in topical form)
and two MSM37,38 (in oral form). Three of the studies
were multi-centred31,37,48. Detailed descriptions for each
of the studies are presented in Tables I(a) (DMSO) and
I(b) (MSM) and Tables II(a) (DMSO) and II(b) (MSM), and
information on adverse events is reported in Table III.RCTs OF DMSOFour double-blind RCTs assessing DMSO have been re-
ported; three placebo-controlled trials (two, two armed49,50
and a three armed study31 and a comparator study48).
The ﬁrst study in 197150 was a single-centred, parallel,
placebo-controlled trial of DMSO in OA knee (N¼ 100) (JA-
DAD 2). The study assessed the efﬁcacy of 50% topical
DMSO ointment vs placebo. Treatment period was 1 month
and the only outcome was patients’ subjective assessment
of pain (Likert scale). It is unclear if DMSO was used as an
adjunctive or sole treatment; the use of rescue medication
was not reported. Both groups reported similar increased
levels of positive analgesic effects, and no statistical analy-
sis was carried out because of the similarity of treatment re-
sponse. The dose of DMSO used in this study is just below
the suggested optimal 60% concentration and it failed to
show any signiﬁcant statistical or clinical beneﬁt.
Eberhardt et al.’s49 double-blind, placebo-controlled par-
allel study evaluated 25% DMSO gel (suboptimal dose)
(N¼ 56) vs placebo gel (N¼ 56) in OA knee (diagnosed ra-
diographically) who had not received anti-inﬂammatory
drugs for the previous 3 months (Tables I and II provide re-
porting details JADAD 4). The treatment period was only 3
weeks and DMSO was used as a sole treatment; the use of
rescue medication was not reported. The primary outcome
measure was pain reduction on resting, on loading and on
palpation using visual analogue scales (VASs). DMSO
showed signiﬁcant reduction vs placebo in all primary out-
comes (resting pain, P¼ 0.015; loading pain P¼ 0.019;
and palpation P¼ 0.029). The dose in this study was below
the suggested optimal level of 60% concentration yet signif-
icant statistical effects were identiﬁed. Neither comparison
between group baseline characteristics, nor a power calcu-
lation was reported. Drop out rates were low, and only minor
adverse events were reported.
Table I(a)
RCTs of DMSO in the treatment of OA
Author Jaded score Study design Joint
location
Sample size Intervention/control Outcome measures Main result
Vuopala
et al.50
2
Blinding: 2
Randomisation: 0
Withdrawals: 0
Single-centre,
double-blind,
placebo-
controlled
Knee 100 (50
DMSO;
50
placebo)
1. 50% DMSO
ointment
2. Placebo
Treatment
period: 1 month
Primary outcomes:
Likert scale of patient
assessment of
analgesic effect
Evaluated at 1 month
No inferential statistical group
analysis performed
Authors state that DMSO has the same
effect as placebo 76% of DMSO and
76% of placebo patient rated treatment
good or intermediate
Authors reported that no side
effects were observed
Eberhardt
et al.49
4
Blinding: 2
Randomisation: 1
Withdrawals: 1
Double-blind,
placebo-
controlled
Knee 112 (56
DMSO; 56
placebo)
1. 25% DMSO
gel 5e8 cm
2. Placebo
gel 5e8 cm
Dosage: TID
Treatment
period:
3 weeks
Primary outcomes:
change in pain scores for
 Pain under loading VAS
 Pain at rest: Likert scale
 Pain on palpation:
Likert scale
Secondary outcomes:
 Mobility 6-point Likert
 Swelling
 Patient and
physicians global
assess of efﬁcacy
and tolerability
 Adverse events
Evaluated at baseline,
7, 14 and 21 days
All primary efﬁcacy criteria signiﬁcantly
better than placebo
Statistically signiﬁcant and clinically
relevant reduction in loading pain
of mean 42.7 mm (reduction of 64.5%)
in DMSO compared to a signiﬁcant
reduction of 30.8 mm in the placebo
(reduction of 46.5%). Difference in
mean reduction was 11.7 mm
(CI 18.35 to 5.1). DMSO signiﬁcantly
better than placebo (P¼ 0.019)
Pain at rest is signiﬁcantly reduced by
mean of 1.3 in DMSO compared to
0.9 in placebo, P¼ 0.015
Pain on palpation is signiﬁcantly
reduced by mean of 1.5 in DMSO
compared to 1.1 in placebo, P¼ 0.029.
NS group differs for mobility and swelling
PGA and PhGA better for DMSO
than placebo
No serious AE
9 AE DMSO: 12 P
Bookman
et al.31
5
Blinding: 2
Randomisation: 2
Withdrawal: 1
Double-blind,
three arm
comparative,
multi-centre
and placebo-
controlled trial
Knee 248 (84 DF;
80 DMSO;
84 placebo)
1. Topical DFþDMSO
(45.5% wt/wt) 40
drops 4 times daily
2. Topical (45.5% wt/wt)
DMSO 40 drops four
times daily
3. Topical placebo-control
solution (containing
4.5% wt/wt DMSO) 40
drops four times daily
Dosage: four times
a day
Treatment period:
quarter in die (QID)
28 days
Primary outcomes:
 WOMAC pain subscale
Secondary outcomes:
 Physical and stiffness
subscales of (WOMAC)
 Weekly PGA
 Pain on walking
(post hoc)
 Amount of rescue
medication taken
WOMAC pain scores was signiﬁcant
reduced in the DF group [3.9 (95%
(CI) 4.8 to 2.9)] compared to DMSO
[2.5 (CI: 3.3 to 1.7)]; P¼ 0.023 or
placebo [2.5 (CI 3.3 to 1.7)];
P¼ 0.016
DF is signiﬁcantly greater at reducing
pain compared to DMSO and placebo.
DMSO was not superior to placebo
in pain reduction
DF was signiﬁcantly better than DMSO
and placebo for improving physical
function, stiffness, pain on walking
and PGA
NSD for adverse event reporting
No therapeutic beneﬁt on efﬁcacy
variables for DMSO as vehicle
control (45.5%) vs placebo
solution (4.5% DMSO)
(continued on next page)
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1280 S. Brien et al.: DMSO and MSM in osteoarthritisBookman et al.31 conducted a three armed randomised,
double-blind, multi-centre, three armed trial in OA knee to
assess the efﬁcacy of; topical DF in a carrier solution using
DMSO (45.5% wt/wt); DMSO as a control (45.5% concen-
tration); placebo, a very low level of DMSO for blinding pur-
poses (JADAD 5). This is the sole study using DMSO in an
inactive dose in the placebo to ensure blinding. Patients di-
agnosed with radiological OA knee for at least 6 months
with current moderate or severe pain were included
(N¼ 248). The 4 weeks’ treatment began after a 1-week
washout for all medication; no rescue medication was
used, DMSO was the sole treatment. This study was in-
cluded since it was possible to compare DMSO to placebo;
however, the study was not powered to assess this as its
primary outcome. Primary outcome was the VAS pain sub-
scale of the Western Ontario and McMaster Universities
(WOMAC) OA Index. The mean change in pain scores
was signiﬁcantly greater with topical DF in DMSO carrier
treatment [3.0 (95% conﬁdence interval (CI) 4.9 to
2.9)] than DMSO [2.5 (CI 3.3 to 1.7)], P¼ 0.023 or
placebo [2.5 (CI 3.3 to 1.7)], P¼ 0.016. DMSO was
shown to have the same analgesic effect as placebo. This
study compares DMSO with topical DF and does not reﬂect
a comparison with standard conventional treatment since
DF is generally taken orally. A power calculation indicated
that 40 patients per group would be needed to detect a dif-
ference of 3 (out of 20) in WOMAC pain scores; the sample
size was doubled, so power was adequate. The clinical ef-
fect size is limited; 19.5 mm VAS change for DF in DMSO
and 12.5 mm for DMSO difference compared to 28.6 mm
oral for COX-2 inhibitors51. DMSO was used in this study
as a carrier rather than as a therapeutic agent, however,
the dosage prescribed, although lower than recommended
in normal clinical practice (45.5 vs 60%), it was comparable
to other clinical trials. No signiﬁcant statistical or meaningful
clinical effect was observed.
The last DMSO study, a comparator study48, an equiva-
lence trial, was performed comparing DMSO to standard
conventional treatment i.e., DF (JADAD 2). This was
a multi-centre phase IV trial which assessed the effect of
topical (10%) DMSO vs topical DF in 221 patients
(N¼ 111 DMSO; N¼ 110 DF) with radiological conﬁrmed
acute inﬂamed OA knee for 21 days. All medication ceased
before entry (steroids for 1 month and analgesics and anti-
inﬂammatory agents for 7 days); the use of rescue medica-
tion was not reported. The primary outcome was pain on
movement (VAS). A clinically relevant reduction in pain
was observed for both treatments (mean VAS reduction:
28.4 19.9 mm DMSO compared to 24.1 23.6 in the DF
group) and no signiﬁcant differences were observed be-
tween treatment groups [CI 3.5 to þ8.6 mm] suggesting
equivalence of both treatments. However, no deﬁnition of
equivalence was given and it is unclear if this study was
powered as a formal equivalence trial. A low dose of
DMSO was used in this trial (10%) but in spite of this the
study reported clinically meaningful and statistical signiﬁ-
cant beneﬁts. Adverse drug reactions were mild and local-
ised to skin reactions.RCTs OF MSMTwo double-blind, placebo-controlled trials have as-
sessed MSM37,38. Usha and Naidu37 performed a multi-
centred double-blind, parallel and placebo-controlled trial
(Tables I and II provide reporting details, JADAD 4) recruit-
ing (N¼ 118) patients with mild to moderate OA knee
(Lequesne diagnostic criteria). Patients with current
Table I(b)
RCTs of MSM in the treatment of OA
Author Jaded score Study design Joint
location
Sample size Intervention/control Outcome measures Main result
Usha and
Naidu37
4
Blinding: 2
Randomisation: 1
Withdrawal: 1
Double-blind,
parallel,
placebo-
controlled
Knee 118 (27 Glu;
27 MSM; 28
GluþMSM;
24 placebo)
1. Glu 500 mg/d and MSM
placebo (both capsules)
2. MSM 1500 mg/d and Glu
placebo (both capsules)
3. Glu 500 mg/d and
MSM 1500 mg/d
(capsule)
4. Glu and MSM placebo
(both capsules)
All treatments were two
capsules taken three
times daily
Dosage: three times
a day
Treatment period:
12 weeks
Primary outcomes:
 Responder e i.e., a 3-point
decrease in Lequesne index
from baseline plus physician
overall efﬁcacy assessment
of good or fair
 Pain intensity VAS
 Joint mobility
 PGA and PhGA
 Lequesne index
Secondary outcomes:
 Physician completed pain
and swelling Likert
 15 m walking time
 Consumption of
rescue medication
Efﬁcacy and safety
evaluated at baseline
2, 4, 8 and 12 weeks
Signiﬁcant decrease in mean pain index
from 1.74 to 0.65 with Glu (P< 0.001) and
a signiﬁcant decrease from 1.53 to 0.74
with MSM
Combined Glu and MSM resulted in a
signiﬁcant decrease in mean pain of
1.7e0.36 (P< 0.001). Placebo did
not show any signiﬁcant change
(1.57e1.16)
Combination of Glu and MSM was
superior to individual and placebo for
number of variables: pain index, swelling
index: P< 0.05, joint function, walking time,
joint mobility index and overall function ability
Combination was more effective in
reducing pain than individual therapy.
MSM was superior to placebo and
inferior to Glu in this trial
Kim et al.38 5
Blinding: 2
Randomisation: 2
Withdrawals: 1
Single-centre,
RCT, double-
blind, placebo-
controlled
Knee 50 (MSM,
25;
placebo,
25)
1. Oral MSM, 3 g
(DMSO content
<0.05%)*
2. Placebo
Dosage frequency:
BID
Treatment period:
12 weeks
Primary outcomes (at baseline,
2, 4, 8 and 12 weeks):
 Pain, physical function and
stiffness and total
scores (WOMAC)
Secondary outcomes (at
baseline and 12 weeks):
 PGA and PhGA (5-point
Likert scale)
 Short Form (SF)-36
 Labs (CRP, homocysteine,
ESR and MDA)
 Use of rescue analgesia
weekly by telephone e
compliance and AE
Primary: MSM signiﬁcantly improved
WOMAC pain (14.6 vs 7.3, P¼ 0.041)
and physical function (15.7 vs 8.8,
P¼ 0.045) compared to placebo. Neither
signiﬁcant difference noted for stiffness
(10.1 vs 6.5, P¼ 0.32) nor total
scores 13.4 vs 7.5, P¼ 0.054)
compared to placebo
Secondary: no signiﬁcant difference in
decrease in either patient (P¼ 0.549) or
physician (0.447) GA. Signiﬁcant
decreases in MDA (P¼ 0.01) and
homocysteine (P¼ 0.004) observed in
MSM compared to placebo
AEs were minor (notably GI, fatigue, and
insomnia) and no group difference in
levels reported (MSM, N¼ 21; placebo,
N¼ 19)
Authors reported that signiﬁcant
differences found in MSM were not
necessarily clinically relevant when
compared to NSAID treatment changes
on these measures
*1-week step-up dose from 2 g/d until 6 g/d reached. 1
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Table II(a)
Further methodological details of RCT for DMSO
Author Sex ratio (M:F) Mean age of
sample group
(year) (range)
Inclusion criteria
stated
Exclusion
criteria stated
Concomitant
medications
recorded
Consort
statement
Compliance
assessed
Power calculation
performed, statistical
analysis
Baseline
characteristics
Dropouts Comment
Vuopala
et al.50
No information No differen-
tiation between
groups’ ages.
Overall mean
age 60
No
1. OA of the
knee with
continuous
pain for
several years
No No information No No No Not reported No information  No details of blinding or random
isation process noted although
numbered tubes used in blind
manner
 Query blinding of medication due
to smell?
 Short treatment period
 Treatment dose not at
therapeutic levels
 No baseline measures reported
 No power calculation or
justiﬁcation of sample size
 Objective assessment
 No statistical analysis
 Paper publication date is prior to
stricter methods now introduced
Eberhardt
et al.49
DMSO, 28:28
Placebo, 27:29
DMSO, 62.3
(34e81)
Placebo, 63.3
(38e81)
Yes
1. Radiological
and clinical
diagnosis of
OA of the
knee in the
past 5 years.
2. Only one joint
requiring
treatment
3. Age 18e80
Yes
1. Treatment
needed in
greater than 1
joint
2. Other
inﬂammation
diseases of
the joint
3. Treatment for
the joint in the
last 3 months
4. Local or
systemic
treatment in
previous
1 day or
7 days,
respectively
All anti-
rheumatic
therapy stopped
3 months,
systemic
therapy topped 7
days and local
therapy stopped
24 h before start
of study
No mention of
rescue
medication
No No No
ITT
Primary outcomes:
ANOVA, other
outcomes:
contingency
board method and
t test
No signiﬁcant
group differences
at baseline for
symptom duration,
age, height,
weight, length of
activation of
current symptoms
Total: 4%
DMSO: 3 (5%)
2 LOE
1 Other
Placebo:
1 (2%)
1 SE
 Short treatment period
 Treatment dose not at
therapeutic levels
 Use of Likert scale to assess
pain at rest and palpation
 No power calculation performed
 Lower age range unusual for this
condition
 Patients who were pain free
could cease study medication
and stop trial before day 21
 Short washout periods for
systemic and local
Bookman
et al.31
Total, 91:157
DF, 32:52
DMSO, 26:54
Placebo, 33:51
DF: 62.5
DMSO: 62.1
Placebo: 60.8
Yes
1. Radiological
conﬁrmation
of primary OA
in at least one
knee
2. Moderate
pain
(WOMAC
pain
subscale)
in previous 2
weeks
Yes
1. Secondary
arthritis
2. Use of an
other topical
agent at site
3. Corticosteroid
use
Rescue medica-
tion allowed ex-
cept 24 h before
baseline and
ﬁnal WOMAC
assessments
Prohibited
medication
stopped 1 week
before baseline
assessment
Yes Yes by
weighing
bottles at
weekly visit
N¼ 40 per group
plus 10 for drop outs,
to detect a difference
of 3, 4 or 5 units in
WOMAC pain 80%
power and a¼ 0.05
ITT analysis
Primary outcomes:
ANCOVA
No signiﬁcant
group difference
for demographics,
baseline knee
pain, radiographic
status or
compliance
Total: 16%
DF: 10 (12%)
AE: 5
LOE: 2
Other: 3
DMSO: 14
(18%)
AE: 3
LOE: 8
Other: 3
Placebo: 15
(18%)
AE: 0
LOE: 10
Other: 5
 Aim of the study was not to
evaluate the efﬁcacy of DMSO.
Is power therefore adequate?
 DMSO was used in this study to
enhance absorption of DF
 Multi-centre trial e high external
validity
 Compliance did not differ be
tween groups
 Drop out rates due to lack of
effect was signiﬁcant lower in DF
compared to DMSO and placebo
 Only 1-week washout of pro
hibited medication before
baseline assessment
 Scale of improvement with
DF comparable to that of oral
intake of DF
 Clinical signiﬁcance of
results not reported by author
 Treatment period not
long enough to assess AE
 DMSO dose not at therapeutic
level
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1283Osteoarthritis and Cartilage Vol. 16, No. 11symptoms (>6 months) were randomised to one of four oral
treatments: glucosamine 1500 mg/d; MSM 1500 mg/d;
combination of MSM (1500 mg/d) and glucosamine
(1500 mg/d) or placebo, for 12 weeks. The dosage used
is lower than that recommended for clinical practice. No
other treatment was allowed during the trial, but rescue
medication was permitted. Treatment began after a 2-
week washout. Main outcome measures were pain and
swelling indices (4-point scale), VAS pain, joint mobility, pa-
tients and physician global assessment and the disease
speciﬁc Lequesne index. The primary outcome was ‘‘re-
sponder rate’’ deﬁned by a >3-point decrease in Lequesne
index together with investigator assessment of efﬁcacy;
‘‘good’’ or ‘‘fair’’. The power calculation was based on
VAS of pain, and not the responder rate, and identiﬁed
120 patients would be required. No deﬁnitive evaluation of
MSM can be evaluated as the results for the primary out-
come was not reported; changes in VAS pain were reported
but no statistical results were described. Signiﬁcant de-
creases in pain scores were reported for the pain index
(secondary outcome), from baseline to end of treatment in
the glucosamine (P< 0.001), MSM (P< 0.001) and in the
combination of glucosamine and MSM (P< 0.05); all three
combinations were superior to placebo. Results are pre-
sented as means at baseline and 12 weeks but analysis us-
ing analysis of covariance (ANCOVA) at 12 weeks with
baseline values as covariates would have been more ap-
propriate to compare the main treatments effects between
the four groups utilising the factorial nature of the trial.
The main adverse event was diarrhoea which occurred in
5% of the participants in the study.
Kim et al.38 compared oral MSM (2-week step-up dose
from 2 g/d to 6 g/d) vs placebo over 12 weeks in a double-
blind RCT (JADAD 5). Twenty-ﬁve patients with American
College of Rheumatology (ACR) mild to moderate knee OA
with regular persistent pain over 3 months entered treatment
after a 1-week washout period from all other therapies. The
primary outcome measure was the disease speciﬁc WO-
MAC.Both treatments resulted in beneﬁt in allmeasured vari-
ables, with signiﬁcant differences between treatments in
favour of MSM for pain (P¼ 0.041) and physical function
(P¼ 0.045). Adverse events were minor and mainly GI re-
lated. This study used a dose of MSM in upper range of the
suggested therapeutic level for a clinically appropriate period.
The ﬁndings suggest efﬁcacy for MSM but the improvement
of 14.6 mm (pain VAS) is a lower effect size than reported
in trials using COX-2 inhibitor Celecoxib (28.6 mm)51. How-
ever, our sensitivity analysis conﬁrms that this study was
not sufﬁciently powered; 50 subjects were recruited, 25 in
each of the two arms. The reported power calculation was
based on anticipated improvements over baseline rather
than on a clinical difference between the two treatment
groups. As the observed difference between the improve-
ments in pain from baseline for the two treatments was
7.3 mm (3.5 mm S.E.M.) greater on active MSM than on pla-
cebo, with a signiﬁcance of P¼ 0.04, this study had a power
of 55% to detect such a difference using a 5% level of signif-
icance. The positive outcome may be overestimated be-
cause baseline recordings were measured after washout,
so any deterioration in pain for this washout week may
have enhanced the apparent treatment effect.Discussion
Biological mechanisms of action for DMSO and MSM pro-
vide support for their proposed anti-inﬂammatory52 and
Table II(b)
Further methodological details of RCT for MSM
Author Sex ratio
(M:F)
Mean age
of sample
group (year)
(range)
Inclusion
criteria stated
Exclusion
criteria stated
Concomitant
medications
recorded
Consort
statement
Compliance
assessed
Power
calculation
performed,
statistical
analysis
Baseline
characteristics
Dropouts Comment
Kim
et al.38
MSM,
9:12
Placebo,
6:13
MSM:
56.6
Placebo:
55.6
Yes
1. Knee OA
according to
ACR criteria
functional
class 1e3
and
radiographic
conﬁrmed
Kellgrene
Lawrence
(KeL)
grades 2e3
2. Regular
arthritic
pain for >3
months
3. Appropriate
high
scores in PGA
and VAS
4. Age> 40
years
Yes
1. Severe OA
(KeL IV)
2. Other types of
arthritis or
chronic pain
3. Corticosteroid
use in previ
ous 3 months
All medication
(NSAID, CAM)
stopped days prior
to baseline
Rescue analgesia
was permitted
Yes Yes, weekly
telephone calls
and pills counted
at end of study
Yes
ITT analysis
Group differences
in baseline to week
12 by t test
No signiﬁcant
group
differences at
baseline
for sex, age,
height,
weight and
symptom
duration, NSAID
use, MSM or
DMSO use,
ACR classiﬁcation,
baseline VAS
scores, PGA or
PhGA scores,
and radiological
stage
Total: 10 (20%)
MSM: 4 (16%)
2 LOE
1 SE
1 Lost to follow-up
Placebo: 6 (24%)
5 LOE
1 Lost to follow-up
 Dosage and treatment
duration appropriate
 Demographic information
only about patients who
ﬁnished the trial
 Short washout period of
only 7 days so may
enhance apparent
treatment effect
 Compliance in both groups
was good (MSM 89.5 and
placebo 90.5%)
 Power calculation based
on 25% improvement of
WOMAC pain scale at 12
weeks with 80% power,
P¼ 0.05 identiﬁed N¼ 22
per group and allowed for
10% drop our rate
(i.e., N¼ 25). But did not
consider differences be
tween treatment groups
 Authors report no ‘‘major’’
difference between
treatment groups at
baseline
 Longitudinal analysis
could have been
completed
 Authors reported that
length of trial inadequate,
with WOMAC scales de
creasing at 12 weeks
hence further monitoring
would be needed.
 Patients recruited were not
as severe as other NSAID
trials (mainly ACR I and II)
 Exclusion criteria included
patients with a body mass
index (BMI) >45 kg/m2
 No statistical analysis of
adverse events
Usha
and
Naidu37
Glu, 12:18
MSM, 8:22
Both, 10:20
Placebo,
12:16
Glu: 52
MSM: 51
Both: 52
Placebo: 50
(40e70)
Yes
1. Radiological
evidence of
mild to
moderate
severity of
knee OA
2. Minimum
duration of
symptoms for
6 months
3. Lequesne
score between
8 and 18
4. Age 40e70
years
5. No NSAID in
previous 2/52
Yes
1. Severe OA or
<grade 1 OA
2. Any anti-
inﬂammatory
medication
3. Involved in an
other clinical trial
in last 30 days
All medication
stopped 2 weeks
prior paracetamol
as rescue
medication
No Yes
Pill counting
Yes
N¼ 120 to detect
20% score on VAS,
80% power and
a¼ 0.05
ITT analysis
Primary outcomes:
Analysis Fisher’s
two-tailed test
Other: ANOVA,
Mann Whitney or
Student’s t test for
other variables
No signiﬁcant
group differences
at baseline for age,
height, weight and
symptom duration,
baseline VAS
scores,
concomitant use of
analgesic and
radiological stage
Total: 8%
Glu: 3 (10%)
MSM: 3 (10%)
Combination:
2 (7%)
Placebo: 4 (13%)
All lost due to
follow-up after
4 weeks therapy
 Aim of study was to assess
efﬁcacy of all three treat
ments vs placebo
 Dosage and treatment du
ration appropriate
 Results of primary outcome
‘‘responder rates’’ were not
reported. No clear
deﬁnition of the primary
and secondary outcomes
 Compliance good in 80% of
patients, no signiﬁcant
group differences
 Drug taken as capsules
 All participants had to stop
OA treatment prior to the
study
 CI not recorded
 No statistical results re
ported for various variables
e.g., VAS pain, rescue
medication, walking time,
joint motility
 Analysis was based on re
sponder rates (even though
power was based on differ
ence in VAS means)
 ANOVA was used for the
comparisons of the
Lequesne pain and
swelling index, the results
presented as means at
baseline and 12 weeks
(with SD at each time
period). More appropriate
to have carried out an
ANCOVA on the scores at
12 weeks with baseline
values as covariates and
comparisons made
between the four groups
using the factorial nature of
the trial
 Longitudinal analysis could
have been performed
Table III
Adverse effects
Author Nutritional
supplement
Adverse events
noted?
How noted and
by whom?
Total no. of
adverse events
Total no. of
patient
experiencing
adverse effect
Observed adverse effects
DMSO studies
Vuopala
et al.50
DMSO No No information No information No information No adverse effects noted.
Eberhardt
et al.49
DMSO Yes Documentation of
adverse events by the
patient or questioning
by the examiner
DMSO: 5
Placebo: 4
DMSO:
9 (16%)
Placebo:
10 (18%)
DMSO: slight redness of skin (5),
burning sensation (1), taste sensation (2),
diarrhoea (1), vomiting (1)
Placebo: slight redness of skin (7), itching (2),
febrile infection (2), cough (1)
Koenen DMSO Yes No information No information DMSO: 17 (16%)
DF: 5 (5%)
Mild and localised skin reactions
Bookman
et al.31
DMSO Yes Patient diaries DF: 9
DMSO:
10
Placebo: 9
DF: 76 (90%)
DMSO: 54 (68%)
Placebo: 23 (27%)
Most frequent AE was skin dryness or ﬂakiness
at application site and occurred in 36% DF, 15%
DMSO and 1% placebo
No signiﬁcant group differences in GI events
DF: constipation (1), diarrhoea (1), dyspepsia (6),
halitosis (4), body odour (2), dry skin (30), paraesthesia
(12), rash (11), pruritus (9)
DMSO: constipation (1), diarrhoea (2), dyspepsia (4),
nausea (4), vomiting (1), halitosis (1), dry skin (11),
paraesthesia (18), rash (6), pruritus (6)
Placebo: constipation (1), diarrhoea (3), dyspepsia (5),
nausea (1), vomiting (1), dry skin (1), paraesthesia (5),
rash (3), pruritus (3)
MSM studies
Usha and
Naidu37
MSM Yes Reported by the
patient or questioning
at visit and recording
in case report
No information No information Authors do not state in which treatment group the adverse
effect occurred in. Minor GI discomfort. Main adverse event
was diarrhoea, occurred in 5% patients. No patients stopped
trial due to adverse drug reactions
Kim et al.38 MSM Yes Questionnaire
assessing GI and
neurotoxic symptoms
at baseline and 12 weeks
No information MSM: 12 (57%)
Placebo: 11 (58%)
All minor symptoms
No statistical evaluation of adverse events
MSM: bloating (14%), constipation (10%), indigestion (5%),
fatigue (10%), concentration problems (5%), insomnia (10%)
and headaches (5%)
Placebo: bloating (10%), constipation (10%),
indigestion (5%), fatigue (16%), concentration
problems (5%), insomnia (5%) and headaches (5%)
AE: adverse event.
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1287Osteoarthritis and Cartilage Vol. 16, No. 11analgesic17e19action. The history, pharmacology and rele-
vant pre-clinical studies of DMSO/MSM have been re-
viewed comprehensively elsewhere15,16. This review
conﬁrms that currently there is no deﬁnitive evidence for
the efﬁcacy of either DMSO or MSM in OA. The four studies
evaluating DMSO trials were conﬂicting, two (evaluating
a total of 333 patients) were positive48,49 and two (evaluat-
ing a total of 348 patients) were negative31,50. The two MSM
studies37,38 assessed a total of 168 patients and reported
signiﬁcant effects of MSM over placebo. These results ini-
tially are promising but no deﬁnitive conclusion can be
drawn for the efﬁcacy of MSM in OA knee due the method-
ological issues highlighted. These include the lack of report-
ing of primary outcome variables by Usha and Naidu trial37;
and inadequate power and non-clinically relevant improve-
ments identiﬁed for Kim et al.38.
This review has highlighted the need to identify the opti-
mal treatment period and dose of DMSO and MSM in OA.
Only two of the six studies (both the MSM trials37,38) treated
for an apparently clinically relevant time period (more than 3
months). The DMSO trials only medicated for 3e4 weeks
which appears to be an insufﬁcient time to adequately eval-
uate treatment. DMSO was used topically in all trials in
doses below 50% suggesting suboptimal treatment accord-
ing to current recommendations. However, signiﬁcant posi-
tive ﬁndings were identiﬁed in two studies using low dose
concentrations (25%49 and 10%48 vs the recommended
60%) taken for inadequate time period. These contradictory
ﬁndings have also been identiﬁed previously in both the
early uncontrolled trials of DMSO for OA in humans14
(some showing beneﬁcial effects12,54,55 including a multi-
centre outcome trial53 while others did not56) as well as in
animal models57e59. This suggests the current guidelines
may be incorrect and emphasises the need for a phase II
trial. A number of factors may explain these inconsistencies.
Although variation in the dosages makes comparison be-
tween trials difﬁcult and can contribute to variability in trial
outcomes [as observed in the supplementation trials of
omega-3 essential fatty acids (EFA)60], it is unlikely that
this is the case with DMSO given that only low not high
dose studies demonstrated an effect. Further trials are
needed to clarify and explain these anomalous results.
Five of the six studies clearly evaluated DMSO or MSM
as an alternative rather than an adjunctive treat-
ment31,37,38,48,49. All the studies identiﬁed assessed OA
knee with pain as the primary outcome in all the studies
with relevant validated outcome measures. Only two studies
employed the disease speciﬁc WOMAC as a primary out-
come31,38; with the others reporting either VAS pain37,48, Lik-
ert pain49 or assessment of pain relief50 as one of the primary
outcomes. All but one study50 clearly stated the inclusion and
exclusion criteria. The studies were pragmatic and generally
representative of this condition involving the elderly with ap-
propriate comorbidity thus increasing the external validity.
All the studies, except Vuopala et al.50, recruited participants
with radiological evidence of OA although only two37,38 used
formal X-ray classiﬁcation criteria and excluded severe OA
which is clinically more difﬁcult to treat. Pain was a selection
criterion for three of the six studies ranging from current pain
(over 2 weeks)31 to longer-term pain (3e6 months). Patients
were excluded if they had recent conventional treat-
ment31,37,38,49 or other secondary arthritis or other painful
conditions31,38,48,49.
The methodology quality of the studies was variable. Four
of the six studies31,37,38,49, obtained high JADAD scores
(i.e., a score of 4 or 5) with two obtaining the maximum
score of 531,38. The remaining two studies received lowscores due to lack of description of blinding48, randomisa-
tion and dropouts50. In addition, the issue of blinding was
questionable in all but one of the DMSO studies31 as
DMSO has a pungent smell.
The quality of adverse event reporting was poor; group
differences were assessed in only one study31 and causal-
ity was not reported in any studies consequently it was not
possible to identify an adverse reaction from a study event.
One study did not report any adverse events50 and two did
not identify which events arose in which treatment
group37,48. The number of adverse events in the trials
ranges from 1648,50 to 68%31 in the DMSO studies and
57% for the only MSM study38 to report it. No serious ad-
verse events were reported, the majority of events were mi-
nor and related to localised skin reactions and GI
symptoms. DMSO elicited more skin reactions than oral
MSM but minor GI complaints were reported for both sup-
plements31,37,38,49. Body odour is one of the main adverse
effects that are associated with DMSO but only one study31
noted this adverse effect, suggesting poor reporting. Drop
out rates due to adverse events were very low, and coupled
with the adverse event data, this suggests that these sup-
plements are only associated with minor and transitory ad-
verse events when taken for short time periods but also that
longer-term evaluation is essential. Standard conventional
treatment causes 9e39%3,61e63 of OA patients to experi-
ence GI adverse events compared to 4e15% in those tak-
ing DMSO. However, the shorter time periods reported do
not provide information relevant to longer-term use of these
supplements in large populations. Based on these data it is
currently difﬁcult to deﬁnitively evaluate the safety proﬁle of
DMSO or MSM.
This is the ﬁrst systematic review assessing DMSO, and
the ﬁrst to assess the combination of both DMSO and MSM
in the treatment of OA. We have highlighted the necessity
for improved design, analysis and reporting in future stud-
ies. Despite the plausible biological mechanism for their
purported action, further rigorous investigations are need
to assess their efﬁcacy as an adjunctive or alternative treat-
ment in OA, as it is currently impossible to arrive at deﬁni-
tive conclusion about their effectiveness. Some of the
data shows promise and therefore further studies are war-
ranted as both supplements may have potential as a safe
alternative to NSAIDs. The evidence for MSM is stronger
suggesting that it may be more beneﬁcial to DMSO. Studies
to evaluate their safety and in particular phase II studies to
evaluate appropriate dose are essential as current data on
safety and dose are limited and constrain the design of fur-
ther RCTs. Subsequent efﬁcacy studies are also needed
with adequately power to detect a signiﬁcant effect size,
an adequate treatment period, use of appropriate outcome
measures and appropriate blinding. In addition, a compara-
tor trial of MSM against standard conventional treatment
would now seem valuable.
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